ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2106

Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation

Nina Kello1, Jacquelyn Nestor2, Tomas Huerta3, Czeslawa Kowal2, Elham Nasiri3, Patricio T. Huerta4, Bruce Volpe5 and Betty Diamond6, 1Rheumatology, Northwell Health, Donald and Barbara Zucker School of Medicine, Manhasset, NY, 2Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, 3Feinstein Institute for Medical Research, Manhasset, NY, 4Feinstein Institue for Medical Research, Manhasset, NY, 5Biomedical Sciences, The Feinstein Institute for Medical Research, Manhasset, NY, 6The Feinstein Institute for Medical Research, Manhasset, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: neuropsychiatric disorders, systemic lupus erythematosus (SLE) and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Cognitive dysfunction affects up to 90% of patients with systemic lupus erythematosus (SLE), however it is grossly under-recognized, the pathogenesis is poorly understood and no treatments are available. The anti-NMDAR antibody, a subset of anti-DNA antibodies termed DNRAbs, has been strongly associated with cognitive impairment, notably spatial memory impairment, in both mouse models and humans. In a mouse model, DNRAb-mediated brain pathology proceeds through two stages: excitotoxic neuron loss, followed by persistent neuroinflammation resulting in alteration in neuronal integrity and spatial memory impairment. Microglia-mediated inflammation is generally becoming well accepted as one of the main mediators of neurodegeneration. In our studies we are investigating the mechanisms of long-term neuronal dysfunction mediated by transient exposure to DNRAb. Also, with the emerging yet unknown role of the renin-angiotensin-system, notably angiotensin II, in microglia-mediated neuroinflammation in neurodegenerative diseases, angiotensin-converting enzyme (ACE) inhibition could be an attractive treatment option to test for preserving cognitive impairment through its effects on C1q and C1q’s inhibitory receptor, LAIR1.

Methods:

Mice immunized with DNRAb and then treated with LPS to breach the blood brain barrier and allow transient access of antibody to the hippocampus, were studied for loss of neuronal dendritic complexity using Golgi and for microglial activation with immunohistochemistry. Spatial memory was assessed with a battery of behavioral tests and CA1 hippocampal neuronal activity was assessed with electrophysiology studies. Microglia were depleted with Colony Stimulating Factor 1 Receptor (CSF1R) inhibitor PLX5622. Mice received centrally acting ACE inhibitor, captopril (or control peripherally acting ACE inhibitor, enalapril), one week after LPS for two weeks. ACE levels in brain tissue was checked before and after treatment. C1q-KO mice and LAIR1-Lyz2-Cre mice were also studied to assess the roles of C1q and LAIR-1 in glia-mediated neuroinflammation.

Results:

DNRAb mice had significantly decreased dendritic complexity (p<0.01), and impaired spatial memory (p<0.01), which was preserved in CSF1R-inhibitor treated mice (p<0.03) and in C1q-KO mice. These findings suggest that activated microglia and C1q are critical mediators of DNRAb-associated neuronal damage and spatial memory impairment. We further showed that centrally acting ACE inhibitors can preserve neuronal dendrite complexity (p<0.03) and cognitive performance (p<0.01) in the mouse model. The effect of captopril was diminished in the LAIR1-Lyz2Cre knockout (p<0.0001), signifying that LAIR1 is important in the protective mechanism of captopril.

Conclusion:

ACE inhibition may be considered as a safe and promising class of therapeutics in cognitive impairment in SLE and represents a strong candidate for future clinical trials aimed at mitigating cognitive dysfunction. Further studies to understand the mechanism of action of ACE inhibitors are needed.


Disclosure: N. Kello, None; J. Nestor, None; T. Huerta, None; C. Kowal, None; E. Nasiri, None; P. T. Huerta, None; B. Volpe, None; B. Diamond, None.

To cite this abstract in AMA style:

Kello N, Nestor J, Huerta T, Kowal C, Nasiri E, Huerta PT, Volpe B, Diamond B. Angiotensin-Converting Enzyme Inhibitors Prevent Spatial Memory Impairment in a Mouse Model of Neuropsychiatric Lupus through LAIR1-Mediated Inhibition of Microglial Activation [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/angiotensin-converting-enzyme-inhibitors-prevent-spatial-memory-impairment-in-a-mouse-model-of-neuropsychiatric-lupus-through-lair1-mediated-inhibition-of-microglial-activation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/angiotensin-converting-enzyme-inhibitors-prevent-spatial-memory-impairment-in-a-mouse-model-of-neuropsychiatric-lupus-through-lair1-mediated-inhibition-of-microglial-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology